Skip to main content
Premium Trial:

Request an Annual Quote

Genomica Announces New Board Member, More Staff Changes

Premium

BOULDER, Colo.--Bioinformatics company Genomica here has announced that Arnold Levine, a codiscoverer of the p53 tumor suppressor gene, has joined the company's board of directors. In addition, the company made two other key staff appointments. Levine is professor of the department of molecular biology at Princeton. Thomas Marr, Genomica's president and CEO, observed, "his scientific expertise is a tremendous asset and will help direct the company as we expand our product base."

Meanwhile, Genomica also announced two new hires. Susan Strong has joined the company as senior director of marketing and sales, and Kenneth Forman is Genomica's new senior director of customer services. "We are continuing to build a solid management infrastructure," Marr commented. Genomica's key product is its Discovery Manager software, which offers a range of tools for clinical and genetic analysis, physical mapping, sequence analysis, and functional analysis. Marr founded the company in 1996 to commercialize tools he and his team developed at the Cold Spring Harbor Laboratory.

Filed under

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.